Marinus Pharmaceuticals Inc (MRNS)

[jtf3]

Seeking alpha contributor replied to your reply Jesse that I posted:

An excellent response to which I have little to add. I've always viewed Ganaxolone's lack of back-conversion into progesterone - by design - as a major advantage that will play out nicely in the real world following commercialisation. Sage simply has a first-mover advantage in PDD & MDD but it's entirely plausible that Marinus will end up owning the superior drug. IV administration in hospitalized patients (severely depressed or suffering from refractory epilepsies) eliminates the bioavailability issue while the CDKL5 data proves that steady, long-term oral administration (capsule form - even more convenient than the oral suspension they were keen on for a while) leads to significant and durable effect, which is fantastic news for patients.